Compare BridgeBio Pharma Inc (BBIO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Tilray Brands Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Tilray Brands Inc trades at $4.76 (market cap $601.34M). The key difference: BridgeBio Pharma Inc is far larger — about 27.6× Tilray Brands Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | TLRY | |
|---|---|---|
Market Cap | $16.61B | $601.34M |
Sector | Health | Health |
52-Week High | $90.17 | $21.00 |
52-Week Low | $47.29 | $3.88 |
Enterprise Value | $18.16B | $768.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
TLRY trades at $4.57, up 2.93% with a bullish technical signal, though recent earnings misses and negative profitability metrics highlight fundamental challenges. The company reported record fiscal 2026 revenue of $915 million but continues to post significant net losses. Analyst sentiment is mixed with 25% buy ratings, while technical indicators show RSI near overbought levels with key support at $4.
Outlook remains cautious due to persistent losses and high valuation multiples, though revenue growth and diversification into beverages offer potential upside. Key risks include execution challenges, cannabis regulatory uncertainty, and competitive pressures in the consumer goods space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
